Jim Cramer: This stock will skyrocket if its chips are approved for China sales

Group 1 - The S&P 500 and Nasdaq surged due to Alphabet's gains and expectations for a Fed interest rate cut in 2025, with a 77% probability of a 25 basis-point reduction [1] - Alphabet's stock rose over 4% following excitement about the launch of Gemini 3, sparking comparisons to OpenAI's ChatGPT [1] - Nvidia's stock increased nearly 2% after the Commerce Secretary indicated potential approval for Nvidia to sell H200 chips in China, with significant implications for the stock price [1] Group 2 - Novo Nordisk shares fell more than 6% after its trial for semaglutide in Alzheimer's treatment did not meet expectations [1] - Eli Lilly, a competitor in the GLP-1 market, saw its stock rise modestly and became the first healthcare company to reach a $1 trillion market cap, with Bernstein raising its price target to $1,300 [1] - Analysts expect Eli Lilly's new oral GLP-1 to exceed revenue expectations of $550 million next year, with Morgan Stanley also increasing its price target for the company [1] Group 3 - Stocks mentioned in the rapid-fire segment included Merck, Carvana, Booking Holdings, and Cummins [1]